Regeneron Pharmaceuticals (NASDAQ: REGN), a biotechnology company, has signed a research collaboration and option licencing agreement with United States-based Vyriad, it was reported yesterday.
The contract has been signed to discover and develop new oncolytic virus-based treatments for treating various forms of cancer.
The companies will also sign a five year research contract to use Regeneron's VelociSuite technologies to design and test Vesicular Stomatitis Virus-based oncolytic virus treatments. The firms will commence a phase two clinical study in 2020 to evaluate Regeneron's PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with Vyriad's oncolytic virus Voyager-V1 in multiple types of cancer. Under the terms of the deal, Vyriad will secure an upfront payment, while Regeneron will make an equity investment in the company.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval